2014-12-08-世界卫生组织-INN_Recommended_List_72_44页_513kb

The World Health Organization recommends 72 new International Nonproprietary Names (INN) for pharmaceutical substances, including complex biologics such as monoclonal antibodies. These names are subject to a rigorous selection process to ensure uniqueness, simplicity, and stability. Examples include aducanumab (anti-amyloid beta peptide antibody), bimekizumab (anti-IL17A/F antibody), and duligotuzumab (anti-ERBB3 antibody). Key features covered in the list include:

• Molecular structures, e.g., dapirolizumab pegol (CD40LG inhibitor conjugated via mPEG linker)
• Amino acid sequences for peptides, e.g., lifastuzumab vedotin (mAb conjugated to auristatin E)
• Chemical synthesis routes, e.g., fosravuconazole (triazole-based antifungal)
• Modifications like glycosylation sites, dimers, or pegylation.

Lists are largely untranslated but include English/French/Spanish translations.

Amendments to prior INN lists (e.g., List 69) have been approved, including:

1. Actoxumab (anti-Clostridium difficile toxin A mAb)
2. Methylnaltrexonii bromidum (revised structure)
3. Egaptivon pegolum (updated chemical composition).

"These names will standardize global drug nomenclature and support patient safety."